title: Successful treatment of high turnover osteoporosis in a patient with adrenocortical insufficiency.
abstract: We present a case of high-turnover osteoporosis associated with substituted adrenocortical insufficiency (Addison's disease) and its successful treatment with calcitonin and calcitriol. A 43-year-old man presented with markedly reduced bone mineral density (BMD) (lumbar spine BMD -3.46 SD below healthy young adults) after thirteen years of glucocorticoid substitution. Interestingly, his osteocalcin levels indicated an unusually high bone turnover and his alkaline phosphatase levels were also increased. Combination treatment with calcitriol and calcitonin was started. Re-evaluation after twelve months revealed a substantial increase in BMD (+6.8% for the lumbar spine, +15% for the left hip). Alkaline phosphatase levels had normalised and osteocalcin was nearly down to normal. In spite of a thorough evaluation, no other cause of osteoporosis was detected. We discuss these findings in view of the existing literature.
authors.affiliation: Department of Rheumatology, Vienna General Hospital, University of Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Aringer
authors.forename: H
authors.initials: H
authors.lastname: Vierhapper
authors.forename: M T
authors.initials: MT
authors.lastname: Graninger
authors.forename: P
authors.initials: P
authors.lastname: Bernecker
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: P
authors.initials: P
authors.lastname: Pietschmann
mesh_terms: D000224:Addison Disease / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use*; D002120:Calcium Channel Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000009:adverse effects; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D002120:Calcium Channel Agonists; D005938:Glucocorticoids; D002116:Calcitonin; D002117:Calcitriol